Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2−) Breast Cancer |
| |
| Institution: | 1. Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China;2. Department of Clinical Laboratory, First Hospital of Changsha, Changsha, China;3. Department of Breast Surgery, Clinical Research Center for Breast Cancer Control and Prevention in Hunan Province, Changsha, China;1. Unità di Oncologia Chirurgica Ricostruttiva della Mammella, “Spedali Riuniti” di Livorno, Breast Unit Integrata di Livorno, Livorno, Italia;2. Department of Surgery “P. Valdoni,” Unit of Plastic and Reconstructive Surgery, “Sapienza” University of Rome, Rome, Italy;3. Department of Diagnostic Imaging, Azienda Ospedaliera Universitaria Senese, Siena, Italy;1. Department of Epidemiology, Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran;2. School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran;3. Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran;4. Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran;5. Infectious Diseases Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;6. Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway;7. Department of Research, Cancer Registry of Norway, Oslo, Norway;1. Cell Biology and Histology, Zoology Department, Faculty of Science, Cairo University, Cairo, Egypt;2. Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt;3. Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt;4. Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt;5. Tissue Culture and Cytogenetics Unit, Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt;1. Department of Research, Bluewater Biotech LLC, New Providence, NJ;2. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD;3. Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY;1. University of Michigan Medical School, Ann Arbor, MI;2. Department of Surgery, The University of Michigan, Ann Arbor, MI |
| |
| Abstract: | BackgroundThe neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been associated with the prognosis in breast cancer (BC). The relationship of the NLR and PLR with chemotherapy sensitivity and prognosis in luminal B-like (human epidermal growth factor receptor 2-negative HER2−]) BC are not well studied.Patients and MethodsThe clinical data from 980 patients with luminal B-like (HER2−) BC from June 2012 to June 2016 were collected. The differences among the variables were calculated using the χ2 test. The associations among the clinicopathologic factors, pretreatment NLR, pretreatment PLR, and disease-free survival (DFS) were analyzed using Kaplan-Meier curves and Cox analyses.ResultsThe median follow-up was 37 months (range, 5-77 months). For the 480 patients who had received neoadjuvant chemotherapy, low pretreatment PLR values were associated with higher pathologic complete response (pCR) rates compared with the high PLR group (15.8% for low vs. 9.2% for high PLR group; P = .027). Multivariate analyses showed that larger tumors, a greater number of lymph nodes involved, a high Ki-67 score, and a high PLR were independent prognostic factors of worse outcomes for the patients with luminal B-like (HER2−) BC. The risk of metastasis and/or recurrence was greater for the high PLR group than for the low PLR group (hazard ratio, 1.576; 95% confidence interval, 1.039-2.390; P = .032). The pretreatment NLR showed no such associations among this cohort of patients.ConclusionsThe results of the present study have shown that the pretreatment PLR is superior to the NLR as a predictor of pCR and DFS outcomes in patients with luminal B-like (HER2−) BC. A low pretreatment PLR was associated with higher pCR rates after neoadjuvant chemotherapy and was an independent predictive factor for better DFS outcomes among patients with luminal B-like (HER2−) BC. |
| |
| Keywords: | Breast cancer Human epidermal growth factor receptor 2-negative NLR Prognostic factor PLR |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
